Next-generation ADC therapies for cancer
MediLink Therapeutics, founded July 8, 2020 in Suzhou, China, is an innovative drug development company specializing in antibody-drug conjugates (ADC) and related technologies. The company's proprietary TMALIN® (Tumor Microenvironment Activable Linker-payload) platform enables next-generation ADC therapeutics that combine the targeting precision of antibodies with the cytotoxic power of small molecules. MediLink has established subsidiaries in Shanghai, Boston, Hong Kong, and Singapore. Key partnerships include worldwide collaboration and license agreements with Roche and BioNTech. The company completed a $70M Series B in 2022 and its lead asset YL201 has received FDA Breakthrough Therapy Designation and Orphan Drug Designation.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2022
Mar 2021
Create a free account to see which investors have funded this company.
Create Free Account
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable...
Pathos is an AI-enabled biotechnology company focused on re-engineering drug development.
Clinical-stage oncology company developing novel CAR-T cell therapies for hematological malignanc...
Clinical-stage biopharma developing and commercializing oncology therapeutics, partnering to glob...
Provides AI and real-world oncology data solutions to life sciences companies, accelerating clini...
